The IFCC-recommended procedure for aspartate aminotransferase (EC 2.6.1.1) was adapted to the centrifugal analyzer and evaluated during five years. The main hindrance to widespread use of the recommended method is the need for pro-incubation with pyridoxal phosphate. The present method includes a 10-mm pro-incubation with pyridoxal phosphate. Extensive evaluation of the method with and without this pro-incubation confirms earlier reports that it eliminates some significant errors, especially for samples from patients with cardiac disease. However, the pre-incubation can be briefer than the recommended 10 mm and still provide acceptable results. 
Materials and Methods

Apparatus
The centrifugalanalyzer we used was a Rotochem IIa-36
Co., Silver Spring, MD 20901). This instrument is under complete computer control, with a 36-space cuvette system. The manufacturer specifies that spectrophotometric precisionis±0.6 milliabsorbanceunit,with a nominal 10-nm or lessbandpass and cuvette temperature control of ±0.05 #{176}C. The automatic device for sample and reagent dispensing was a Rotofill II (American Instrument Co.),with which a 36-placetransferdisccan be loaded in3.5 mm, was used. an initial 60-sdelay.These conditionskeep analysistime short and provide excellent sensitivity. The "kineticrate1" program performs a linearleast-squaresfitof the nine absorbance measurements, calculates the rate of change of absorbance for each sample, and converts these rates to enzyme activity units (U/L). Table 2 shows the precisionof the ASAT assay. Table 3 shows the performance of the assay with use of a College of American Pathologists(CAP) blind triplicate pool survey. Values for the triplicates were very similar at all concentrations, even though analyses were done as much as six months apart.
Results
Precision.
Effects of chloride.
We analyzed patients' samples and controls, using ASAT reagent prepared both with and without the use of HCI to adjust the pH of the reagent (seeabove).
Results without Cl were higher,as shown by the linearregression line slope of 1.09 with an intercept of 0.0 and a correlation coefficient of 1.00 (n 65). Using the Cl--free reagent, we compared sample flushesof salineand de-ionized water. The measured ASAT was not affectedsignificantly by the choice of flush solution, as indicatedby a correlationcoefficient of 1 were seen in the patients with the higher ASAT activities.
All data points <50 U/L are shown in Figure 1 . In addition,
we calculated the reference range for ASAT both with and without pyridoxal phosphate.
To calculate this reference range we plotted the cumulative frequency distribution of the logarithm of ASAT values on normal probability 
We could classify 91 of the 700 patients into four clinical categories, and we present in Figure 2 the effects of measuring serum ASAT with and without pyridoxal phosphate. The patients with liver disease all had above-normal values for serum total bilirubin together with increases in either serum alanine aminotransferase or y-glutamyltransferase. The cardiac patients were in the University of Virginia Coronary Care Unit and had increased creatine kinase isoenzyme 2, and LD-1 > LD-2. The pediatric patients were all younger than 12 years. The requirements for pyridoxal phosphate were most marked in the case of samples from patients in the cardiac and in the pediatric groups.
Studies on the duration of pyridoxal phosphate pre-incubation.
It is often inconvenient to carry out a timed preincubation in a busy routine laboratory. Therefore, we investigated ways of modifying the centrifugal analyzer procedure for ASAT to simplify the pre-incubation step. We measured ASAT with pyridoxal phosphate present in the ci-ketoglutarate solution, but without pre-incubation, in 160 samples, including some 50 samples from the Coronary Care Unit. This procedure still included a lag period before the initial reading, during which the apo-aminotransferase may be activated.
The results obtained on using this modification are shown in Figure 3 in the center chart, where they are compared with the results obtained on the same specimens by the modified IFCC method. ASAT activities in the specimens were also measured with no pyridoxal phosphate in the substrate and again compared with the results obtained by our modified IFCC procedure with pyridoxal phosphate (Figure 2, upper chart) . These studies show that addition of pyridoxal phosphate, even without pre-incubation, markedly improved the results as compared with those obtained with no pyridoxal phosphate in the substrate. For the same group of 160 patients we dispensed reagents in the routine manner but replaced the timed pre-incubation with a minimal pre-incubation.
Because of the nature of the Rotofill II loader-dispenser, some incubation always took placebeforethe startof the analysis: 210 s for the first sample and 30s for the last, We compared thisuncontrolledincubationwith the 10-mm incubation ( Figure 2 , lower chart). This comparison shows an even greaterimprovement with virtually no outlierresults.
Discussion
Ratnaike
and Moss (7) described the importance of including a pyridoxal phosphate pre-incubation step in the assay of plasma ASAT. Patients with various diseases showed different increases in ASAT activity with pyridoxal phosphate present. Rosalki and Bayoumi (6) reported a similar study and observed little activation in the case of both normal individuals and patients with chronic alcoholic liver disease, but marked activation (>25%) in most patients with myocardial infarction.
For samples from nine healthy volunteers, H#{216}rder and Bowers (8) observed a mean increase in ASAT activity of 39%. Numerous other studies attest to the activation by pyridoxal phosphate. Despite these reports, there has been little enthusiasm in clinical chemistry laboratories around the world for measuring ASAT activity with incorporation of the pyridoxal phosphate pre-incubation step. In view of the ease with which new methods can be adapted to the centrifugal analyzer,we developed a modified version of the IFCC provisional recommended procedure for ASAT for this instrument, which has proven to be rapid and extremely precise, as shown in this report.
The present study of 700 patients is larger than previous reports; our results confirm those reports in demonstrating (Figure 2 ), confirming others (6, 7). The changes were largest in sera from patients with evidence of myocardial infarction, whose ASAT activities were 20 to 50% less in the absence of pretreatment with pyridoxal phosphate.
Smaller differences were observed for patients with liver and renal disease. results of the assay using a 10-mm pre-incubation. Extending the pre-incubation in an uncontrolled manner gave an excellent correlation with the modified IFCC method. This result was unexpected in view of the data presented in Bergmeyer et al. (3) , who reported that a 10-mm incubation is required for maximal activity of ASAT. However, their data were derived from studies of two pooled specimens of serum, whereas our studies were performed with relatively fresh individual samples.
Other investigators have recommended incubation times of 7 to 15 mm, but did not show data for shorter times (2, 6, 7) . The results of the present study suggest that a shorter incubation time is adequate for clinical samples.
